Ryan Kofron

机构：APLA Health · ORCID：0000-0002-9748-6531

发表论文 29 篇 · 总被引 2137 次 · h-index 17

代表论文

• Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women (2021 · New England Journal of Medicine · 被引 898)
• Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial (2020 · The Lancet HIV · 被引 179)
• Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial (2018 · PLoS Medicine · 被引 174)
• Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 (2021 · The Journal of Infectious Diseases · 被引 133)
• Long-acting injectable cabotegravir for the prevention of HIV infection (2019 · Current Opinion in HIV and AIDS · 被引 108)
• Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California (2017 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 74)